Strand Genomics is now Strand Life Sciences

Strand Genomics has changed its corporate identity to Strand Life Sciences and the company has come out with a new in-silico (on a computer) ADMET tool.

"The change in corporate identity reflects the expanding focus of the company. Our portfolio of products now extends beyond functional genomics into computational chemistry," said Vijay Chandru, CEO and chairman, Strand Life Sciences.

For the in-silico ADMET (absorption, distribution, metabolism, elimination/excretion) tool, the company has leveraged its core technologies to develop decision-support solutions for powering drug discovery, including in-silico predictive models for drug properties such as ADME and cardiotoxicity.

In addition, Strand has an ongoing research programme in predictive modelling for hepatotoxicity.

The company partners with discovery contract research companies in India to combine in silico with wet lab techniques to offer consulting services starting from compound design to lead generation.

ADMET is a comprehensive tool for modelling and predicting drug-relevant properties of molecules in silico.

It gives users the power to build custom models from scratch, using their own data.